TRPC6 and coronary artery disorder: That is, the body donors with severe coronary heart disease (Donor 2) and the donor with TAVI (Donor 3) showed the least immunoreactive myocardial area (both < 65%), while the remaining 3 donors, with only moderate coronary heart disease and no valvular intervention, all had more than 72% TRPC6-immunoreactive myocardial area.